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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic
involving so far more than 22 million infections and 776,157 deaths. Effective vaccines are
urgently needed to prevent SARS-CoV-2 infections. No vaccines have yet been approved for
licensure by regulatory agencies. Even though host immune responses to SARS-CoV-2 in-
fections are beginning to be unravelled, effective clearance of virus will depend on both
humoral and cellular immunity. Additionally, the presence of Spike (S)-glycoprotein
reactive CD4þ T-cells in the majority of convalescent patients is consistent with its sig-
nificant role in stimulating B and CD8þ T-cells. The search for immunodominant epitopes
relies on experimental evaluation of peptides representing the epitopes from overlapping
peptide libraries which can be costly and labor-intensive. Recent advancements in B- and
T-cell epitope predictions by bioinformatic analysis have led to epitope identifications.
Assessing which peptide epitope can induce potent neutralizing antibodies and robust T-
cell responses is a prerequisite for the selection of effective epitopes to be incorporated in
peptide-based vaccines. This review discusses the roles of B- and T-cells in SARS-CoV-2
infections and experimental validations for the selection of B-, CD4þ and CD8þ T-cell
epitopes which could lead to the construction of a multi-epitope peptide vaccine. Peptide-
based vaccines are known for their low immunogenicity which could be overcome by
incorporating immunostimulatory adjuvants and nanoparticles such as Poly Lactic-co-
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b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 0 19SARS-CoV-2 first emerged in December 2019 in Wuhan (Hubei
Province), causing a pandemic with over 22 million infections
and 776,157 deaths globally (World Health Organization).
Clinical manifestations of COVID-19 vary broadly, ranging
from fever, cough and fatigue to headache, hemoptysis,
diarrhea, dyspnea, and lymphopenia. Severe infections were
reported to lead to pneumonia, acute respiratory distress
syndrome, acute cardiac injury and death [1]. The genome size
of the SARS-CoV-2 is approximately 29.9 kb and its genome
structure is homologous to SARS-CoV-1. The 5’ region consists
of two-thirds of the genome, comprising the orf1ab that en-
codes the orf1ab polyprotein, while the 30region is composed
of one-third of the genome encoding structural proteins
which include surface (S), envelope (E), membrane (M), and
nucleocapsid (N) proteins. Additionally, the SARS-CoV-2 virus
contains 6 accessory proteins: ORF1ab, NS3, NS6, NS7a, NS7b,
and NS8 [2].
Currently, there are over 125 vaccine candidates against
SARS-CoV-2 in development worldwide, with at least 16 of
these being registered for clinical trials [3]. mRNA-1273 is a
novel lipid nanoparticle (LNP)-encapsulating mRNA-based
vaccine that encodes for a full-length, prefusion stabilized
spike (S) protein of SARS-CoV-2. It is co-developed byModerna
and the Vaccine Research Center at the National Institute of
Allergy and Infectious Diseases (NIAID) of NIH. It is currently
in phase III clinical trial. A vectored-vaccine, AZD1222, which
used a chimpanzee viral vector (ChAdOx1) encoding the spike
(S) protein of SARS-CoV-2 was developed by Oxford University
and AstraZeneca, and it is currently in phase II clinical trial.
CoronaVac, formerly known as PiCoVacc, is an inactivated
vaccine developed by Sinovac Biotech. It constitutes thewhole
SARS-CoV-2 virus which carries the receptor binding domain
(RBD) within the S protein as the main immunogen. It is
inactivated with b-propiolactone and mixed with an alum
adjuvant. Sinopharm has just begun testing their inactivated
vaccine candidate in UAE. Both Sinovac's and Sinopharm's
inactivated vaccine candidates are currently in phase III
clinical trials. INO-4800 constitutes a DNA plasmid encoding
the S protein that will be delivered by electroporation via the
CELLCTRA® 2000 electroporator. It is developed by Inovio
Pharmaceuticals and is currently in phase I/II clinical trials.
Furthermore, Novavax has developed a recombinant subunit-
based vaccine, NVX-CoV2373, that is currently in phase I/II
clinical trials. They have genetically modified Sf9 insect cells
to express the recombinant S protein in prefusion state and
incorporated it into a nanoparticle formulation containing
Matrix-M adjuvant. In summary, 19 vaccine candidates with
their associated characteristics that are in clinical trials I, II,
and III against SARS-CoV-2 are presented in [Table 1].
Synthetic peptides are capable of eliciting immune re-
sponses to specific antigenic epitopes while avoiding adverse
effects of immunization. Peptide vaccines can induce broad
immunity against multiple serotypes of the virus by carrying
immunodominant epitopes that are highly conserved be-
tween the serotypes of a virus. Peptide vaccines can be syn-
thesized to contain multiple conserved epitopes that can
target multiple serological variants or strains [4]. Theoreti-
cally, there are several advantages of peptide-based vaccines
over conventional vaccines such as live-attenuated and
inactivated vaccines. Synthetic peptide vaccines can beconstructed to contain only the antigenic region, thus
reducing the reactogenic or allergenic effects of the vaccine.
Synthesis of peptides can be achievedwith relatively low cost,
in conjunction with its higher stability and safety when
compared to live attenuated vaccines. If FDA approved LAV
and IV vaccines against SARS-CoV-2 become available for
immunization, the demand for industrial production to cater
for the entire world's population can pose limitations on its
availability. Since SARS-CoV-2 is highly infectious, growth of
large amounts of viruses poses safety issues in production
facilities. Unlike conventional LAV or IV vaccines, the
composition of the peptide vaccine can be altered with self-
and non-self-antigens such as universal CD4þ T-cell epitopes
to enhance immunogenicity [5]. Moreover, several peptide
epitopes which are capable of activating a number of HLA
restricted T-cell specificities can be incorporated with B-cell
epitopes to form a universal vaccine formulation. Epitope-
based vaccines were found to induce more potent responses
than whole protein vaccines [6]. Effective adjuvants, nano-
particle delivery systems and immunogenic carrier proteins
could be incorporated in the formulation to improve the
immunogenicity of epitope vaccines [7,8].
The elicitation of protective antibodies requires the bind-
ing of peptides representing B-cell epitopes to B-cell receptors
(BCRs) which lead to B-cell activation. B-cell epitopes are
variable in length between 5 and 20 amino acids [9]. Linear B-
cell epitopes are composed of contiguous residues in the pri-
mary structure while discontinuous B-cell epitopes comprise
residues remotely located in the primary structure that are
brought into proximity due to the folding of the protein [10].
For peptide-based vaccines, B-cell epitopes that are linear and
immunogenic are preferentially selected for further in-
vestigations [11]. Cytokines secreted by activated CD4þ T-cells
are required for further activation of B-cells to antibody-
secreting plasma cells.
T-cell epitopes are presented on the surface of an antigen-
presenting cell (APC) where they are bound to MHCmolecules
to induce cellular immunity. One of the key issues in T-cell
epitope prediction is MHC binding, as it is considered a pre-
requisite for T-cell recognition. MHC class I molecules usually
present peptides between 8 and 11 amino acids in length,
whereas the peptides binding to MHC class II may have a
length from 11 to 30 amino acids [12]. MHC class I molecules
are encoded by the HLA-A, -B and eC genes which are widely
expressed inmost cell types in humans. Internalized antigens
are degraded by cytosolic and nuclear proteasomes and the
resulting peptides are transported into the endoplasmic re-
ticulum by the transporter associated with antigen processing
(TAP) protein complex. There, they can bind to human
leukocyte antigen class I (HLA-I) molecules in complex with
beta2-microglobulin (b2m). MHC class II molecules are enco-
ded by the HLA-DP, -DQ, -DR genes which are expressed on
specialized cell types, including professional APCs such as B-
cells, macrophages and dendritic cells. Peptides derived from
degraded extracellular proteins are presented on HLA-II mol-
ecules for recognition by CD4þ T-cells [13]. The recognition of
peptide epitopes by the T-cell receptors (TCR) of CD4þ and
CD8þ T-lymphocytes leads to the induction of cellular im-
mune response that plays a key role in the adaptive immune
system. If sufficient quantities of specific T-cell epitopes are
Table 1 Several vaccine candidates for SARS-CoV-2 in clinical phase.
Candidate Vaccine Characteristics Lead Developer Status Clinical Trial Identifier
mRNA-1273 Lipid nanoparticle-encapsulated mRNA-based vaccine that
encodes for the S protein.
Moderna Phase III NCT04470427
Inactivated vaccine Inactivated novel Coronavirus pneumonia vaccine (Vero cells). Sinopharm Phase III ChiCTR2000034780
CoronaVac b-propiolactone-inactivated and alum-adjuvanted candidate
vaccine.
Sinovac Phase III NCT04456595
AZD1222 Genetically altered and weakened chimpanzee adenovirus vaccine
vector carrying the S protein.
The University of Oxford Phase II/III NCT04400838
Ad5-nCoV Adenovirus type 5 vector that expresses S protein. CanSino Biologicals Phase II NCT04341389
Adjuvanted Recombinant Vaccine Recombinant new Coronavirus vaccine produced in CHO Cells. Anhui Zhifei Longcom Biologic Pharmacy Phase II NCT04466085
Ad26COVS1 Non-replicating Adenovirus type 26 vector. Johnson & Johnson - Janssen Phase I/II NCT04436276
BNT162 4 mRNA vaccine candidates including uridine containing mRNA,
nucleoside-modified mRNA, and self-amplifying mRNA that
encodes trimerized S protein receptor binding domain antigen
formulated with lipid nanoparticles.
BioNTech RNA Pharmaceuticals GmbH Phase I/II NCT04380701
INO-4800 DNA plasmid encoding S protein delivered by electroporation. Inovio Pharmaceuticals Phase I/II NCT04447781
NVX-CoV2373 Recombinant S protein in prefusion state expressed in genetically
engineered Sf9 insect cells and incorporated into a nanoparticle
formulation and saponin-based Matrix-M adjuvant.
Novavax Phase I/II NCT04368988
GX-19 DNA vaccine candidate. Genexine Phase I/II NCT04445389
Gam-COVID-Vac Non-replicating viral vector. Gamaleya Research Institute Phase I/II NCT04437875
LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic
minigene based on domains of selected viral proteins;
administered with antigen-selected viral proteins.
Shenzhen Geno-Immune Medical Institute Phase I/II NCT04276896
bacTRL-Spike DNA plasmid expressing trimeric S protein and a hybrid
transporter protein within Bifidobacterium longum.
Symvivo Corporation Phase I NCT04334980
CVnCOV mRNA-based vaccine mixed with lipid nanoparticles. CureVac Phase I NCT04449276
SCB-2019 Recombinant SARS-CoV-2 trimeric S protein subunit vaccine. Clover Biopharmaceuticals Phase I NCT04405908
COVAX-19 Adjuvanted monovalent recombinant COVID19 vaccine. Vaxine Pty Ltd. Phase I NCT04453852
Pathogen-specific aAPC Artificial antigen-presenting cells modified with lentiviral vector
expressing synthetic minigene based on domains of selected viral
proteins.
Shenzhen Geno-Immune Medical Institute Phase I NCT04299724
Adjuvanted SARS-CoV-2 Sclamp
Protein Subunit Vaccine





























b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 0 21presented by MHC I and II molecules, the activated T-cells will
trigger potent immune responses specific for the pathogen.
Identification of peptides presenting T-cell epitopes on MHC I
and MHC II is integral in the design and construction of
epitope-based vaccines. HLA molecules exhibit high poly-
morphisms and hundreds of different alleles exist in the
human population. Significant overlaps of peptide-binding to
different HLAs have been demonstrated. Specifically, HLA-
A02, A03 and B07 were reported to cover approximately 90%
of the world's population [14]. HLA alleles have been shown to
confer different degrees of viral susceptibility and severity of
diseases. For example, HLA-B*46:01 was identified as the HLA
allele with the fewest predicted binding peptides derived from
SARS-CoV-2 and interestingly, HLA-B*15:03 showed the
greatest binding capacity to highly conserved SARS-CoV-2
peptide epitopes. When analyzing binding affinity pre-
dictions across 145 different HLA-A, B and C alleles, alleles
HLA-A*02:02, HLA-B*15:03 and HLA-C*12:03 were the top HLA
alleles presenting conserved peptides of SARS-CoV-2 [15].The roles of B- and T-cells in SARS-CoV-2
infection
The production of epitope-specific antibodies is a primary
mechanism of protection against viruses. Neutralizing anti-
bodies can inhibit infection by blocking hostecell interactions
and entry of viruses. Antibodies also mediate the destruction
of infected cells by inducing opsonization for phagocytosis,
complement activation, and antibody-dependent cell-medi-
ated cytotoxicity. Coronavirus-induced antibody responses
are quite variable and rather short-lived [16,17]. Patients of
SARS-CoV-2 displayed an antibody responsewithin the first 10
days after the onset of symptoms [18]. Specifically, SARS-CoV-
2 S-specific IgM antibodies were detectable from day 4 after
the onset of symptoms while SARS-CoV-2 S-specific IgG an-
tibodiesweremeasurable from day 7 onwards [19]. SARS-CoV-
2 IgM reached the highest point within 3 weeks of infection
and gradually declined for the following 4 weeks. IgG was
persistently detectable for seven weeks [20]. Further studies
are required to elucidate the persistence of antibodies and
their roles in the prevention of secondary infections. Previous
studies reported the crucial role of T-cells in the elimination of
SARS-CoV-1 [21]. SARS-CoV-1-specific memory T-cells were
found to persist in the peripheral blood of SARS patients for up
to 6 years post-infection despite a lack of specific memory B-
cell response [22]. Ng et al. (2016) demonstrated the presence
of memory T cell responses in SARS-recovered individuals up
to 11 years post-infection [23]. These findings suggested that
SARS-CoV-1-specific T-cell response is important for protec-
tion against re-infection of SARS-CoV-1. For SARS-CoV-1
(2002/03), it was shown that CD4þ T-cell responses corre-
lated well with positive outcomes [16,24]. Helper T-cells
stimulate B-cells and other immune defenders into action,
whereas CD8þ cytotoxic T-cells target and eliminate virus-
infected cells to prevent virus replication and facilitate virus
clearance. Inducing memory T-cells with high proliferation
potential should further enhance the development of effica-
cious vaccines. The severity of the viral disease may depend
on the strength of these T-cell responses [25].The total number of CD4þ and CD8þ T-cells was found to
be dramatically reduced in COVID19 patients, especially those
requiring intensive care. Expression of immune-inhibitory
surface markers such as PD-1 and Tim-3 are known to be
associated with the functional exhaustion of T-cells. ICU pa-
tients with COVID-19 disease showed markedly higher per-
centages of PD-1þCD8þ and CD4þ T-cells as well as Tim-
3þCD4þ T-cells, indicating that SARS-CoV-2 could drive T-
cell exhaustion in COVID-19 patients [26]. Studies also showed
that the levels of IL-2, IL-7, Il-10, TNF-a, G-CSF, IP-10, MCP-1
and MIP-1A were significantly higher in COVID-19 patients
[26,27]. Increased cytokine levels (IL-6, IL-10, and TNF-a),
lymphopenia (low levels of CD4þ and CD8þ T cells), and
decreased IFN-g expression in CD4þ T-cells were reported in
studies that characterized the cytokine storm in patients with
severe COVID-19 [28]. CD8þ T-and NK-cells from COVID-19
patients had increased expression of the inhibitory receptor
NKG2A with diminished productions of CD107a, IFN-g, IL-2
and granzyme B which indicated the functional exhaustion
of NK-and CD8þ T-cells [29].Bioinformatics approach for B- and T-cell epitope
prediction
Peptide-based vaccines comprising short immunogenic pep-
tides have the ability to elicit potent and targeted immune
responses. Bioinformatics approach offers a new in silico
strategy for mapping and identification of potential B- and T-
cell epitopes in the protein sequences of viruses which are
useful for the development of effective multi-epitope vac-
cines. Peptide antigens bound toMHCmolecules are the target
of T-cells. Various bioinformatics tools that allow prediction
of the binding affinity of peptides to MHC class I and II mole-
cules have been developed. Here, we present our in silico pre-
dictions of potential T-cell epitopes. Epitopes were predicted
from the spike (S), membrane (M), and nucleocapsid (N) pro-
teins. First, the protein sequences were retrieved from the
NCBI database (https://www.ncbi.nlm.nih.gov/nuccore/
MN996531.1/). Each sequence is checked on its average anti-
genic propensity using the antigenic peptide prediction tool
(http://imed.med.ucm.es/Tools/antigenic.pl). The protein se-
quences were considered for CD4þ and CD8þ T-cell epitope
selections, respectively. CD4þ T-cell epitopes were predicted
using the MHC-II epitope prediction tool from the Immune
Epitope Database (IEDB, http://tools.iedb.org/mhcii/). This
server uses a combination of different methods including
Artificial Neural Network (ANN) and Quantitative Affinity
Matrix (QAM) for finding the binding affinity of peptides for
class II MHC. A total of 4047 possible epitopes from S, M, and N
proteins were determined using this server. These CD4þ T-
cell epitopes were filtered based on their lowest percentile
rank and IC50 values. Only epitopes with percentile ranks less
than 5.0 and IC50 values of below 50 nM were considered.
Potential CD4þ T-cell epitopes were further refined based on
their immunogenicity score using the IEDB CD4þ T-cell
immunogenicity prediction tool (http://tools.iedb.org/
CD4episcore/). All predicted epitopes have immunogenicity
scores above 80.0. These CD4þ T-cell epitopes were also pre-
dicted based on their capability to induce Th1 immune
Table 2 SARS-CoV-2 CD4þ T-cell epitopes predicted in S,









*Percentile rank of 5.0 was adjusted to be the cut-off indicator for
IEDB MHC-II epitope prediction tool.
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epitope server (http://crdd.osdd.net/raghava/ifnepitope/).
Here, we used a hybrid approach that combines motif-based
models from the pattern discovery software MERCI and Sup-
port Vector Machine (SVM) based models to identify IFN-g
producing peptides. Positive IFN-g producing epitopes were
favoured and used as metrics to select better candidates for
downstream analysis. Simultaneously, CD8þ T-cell epitopes
were predicted using the NetCTL1.2 server (http://www.cbs.
dtu.dk/services/NetCTL/) and epitopes with prediction scores
over 1.0 were selected. Epitopes were further filtered based on
their percentile rank using the IEDB MHC-I epitope prediction
tool (http://tools.iedb.org/mhci/) that also uses QAM and ANN
methods to predict binding affinity. A total of 11 CD4þ T-cell
epitopes [Table 2] and 13 CD8þ T-cell epitopes [Table 3] were
predicted in this manner.
Global population coverage of both HLA class I and II alleles
were investigated against the selected CD4þ and CD8þ epi-
topes respectively using the IEDB population coverage anal-
ysis tool (http://tools.iedb.org/population/). The 11 selected
CD4þ T-cell epitopes were shown to cover 99.36% of global
population alleles whereas the 13 CD8þ T-cell epitopes
exhibited 91.21% global population coverage. All epitopes
were checked to be non-toxic using the ToxinPred module
(https://webs.iiitd.edu.in/raghava/toxinpred/multi_submit.
php). Protein BLAST analysis was conducted to determine
homology of these epitopes with human proteins (https://
blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM ¼blastp&PAGE_
TYPE¼BlastSearch&BLAST_SPEC¼&LINK_LOC¼blasttab).
None of the epitopes shared identity with human protein se-
quences as no alignment score above 67.0 was observed.Table 3 SARS-CoV-2 CD8þ T-cell epitopes predicted in S,










*The cut-off score was adjusted to 1.0 for NetCTL1.2.Therefore, this eliminates chances of the epitopes being
recognized as self-epitopes.
In addition, we have also predicted linear B-cell epitopes in
the S protein using in silico analysis. Linear B-cell epitopes are
favored over conformational B-cell epitopes because linear B-
cell epitopes contain peptides which can represent antigens
for immunizations and antibody production. Using the S
protein sequence from the NCBI database, we used the IEDB
linear B-cell epitope prediction tool (http://tools.
immuneepitope.org/bcell/) to determine conserved se-
quences of the B-cell epitopes. The recognition of B-cell epi-
topes is dependent on the prediction of linear epitopes, its
antigenicity, and its surface accessibility. Therefore, three
different prediction methods that are available in the IEDB
prediction software were utilized. BepiPred Linear Epitope
Prediction 2.0 method was used to predict the linear B-cell
epitopes, while the Kolasker & Tongaokar Antigenicity
method [30] and Emini Surface Accessibility Prediction
method were used to evaluate antigenicity and surface
accessibility of the linear B-cell epitopes. BepiPred2.0 uses a
Random Forest algorithm trained on epitopes and non-
epitopes amino acids determined from antibody-antigen
crystal structures and performs a sequential prediction
smoothing in the end. Lastly, the predicted epitopes were
confirmed by ABCPred (https://webs.iiitd.edu.in/raghava/
abcpred/index.html), which applied ANN using fixed-length
patterns trained on 700 B-cell epitopes and 700 random non-
epitopes in its prediction algorithm with a 65.93% accuracy.
A threshold score of 0.500 was assigned for the BepiPred
method and 34 linear B-cell epitopes were predicted in this
manner. Next, the antigenicity of these B-cell epitopes was
evaluated using a window size of 7 amino acids and a
threshold score of 1.041 based on the Kolasker method. The
surface accessibility of the B-cell epitopes was examined
using a window size of 6 amino acids and a threshold score of
1.000 on the Emini tool. All residueswith a score of above 1.000
on the Emini tool were selected as it indicates an increased
probability for the residue to be located on the surface. Finally,
we confirmed our predictions in the ABCPred server, with a
threshold of 0.51 and using an over-lapping filter. A total of
seven linear B-cell epitopes were predicted after filtering
based on their antigenicity, surface accessibility, and confir-
mation using ABCPred [Table 4]. These seven epitopes have an
average ABCPred score of 0.75 and are exposed on the surface
of the virus, in addition to their high antigenicity score. This
indicates their potential to elicit humoral immune responses.
Various publications have also predicted a number of T-
cell epitopes of SARS-Cov-2 with bioinformatic approaches
depending on high immunogenicity scores, binding affinity
(IC50) to HLA molecules, HLA coverage and IFN-g production.
Here, we list some of the notable results and cross-reference
them with our predicted epitopes. Kiyotani et al. reported
potential epitopes derived from the SARS-CoV-2 for HLAs
commonly present in the Japanese population through
comprehensive bioinformatic screening. The peptides were
predicted using NetMHCv4.0 and NetMHCpanv4.0 software
based on the high binding affinity to HLA class I and II which
led to induction of CD8þ and CD4þ T-cell responses, respec-
tively. They identified 781 HLA-class I and 418 HLA-class II
epitopes that have high homologies to SARS-CoV-1. Two
Table 4 SARS-CoV-2 B-cell epitopes predicted in S protein.















*The cut-off score was adjusted to  0.500 for BepiPred2.0.
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tein were found with high coverage (83%) of the Japanese
population-based on HLA-A frequency [31]. Baruah et al.
identified five CD8þ T-cell epitopes and five discontinuous B-
cell epitopes in the S glycoprotein. All five CD8þ T-cell epi-
topes were classified as strong binders to their corresponding
MHC class I supertype representatives (A2, A3, B7, B44, and
B62) which accounted for themajor HLA-A and B distributions
in China. Importantly, these epitopes were observed to bind
with the peptide-binding groove of MHC class I molecules
during molecular dynamic simulations. Therefore, these epi-
topes could serve as potent T-cell epitopes for the develop-
ment of SARS-CoV-2 vaccines. Sequential B-cell epitopes in
the S protein were identified with BepiPred 2.0 and over-
lapping filters with ABCPred. To further identify discontin-
uous B-cell epitopes, Ellipro was used to model the S protein
structure in Raptor X [32]. Sahoo et al. identified 36 epitopes for
class I MHC and 25 epitopes for class II MHC molecules from
the ORF1ab polypeptide, surface glycoprotein, membrane
glycoprotein and nucleocapsid phosphoprotein of SARS-CoV-
2 based on the maximum binding score to HLA molecules.
These epitopes were predicted by using Propred and Propred1
immunoinformatics tools which cover the maximum number
of HLAs compared to other epitope prediction tools. Among
the seven T-cell epitopes identified in the S protein, peptide
KIADYNYKL was predicted to bind to the highest number of
MHC class I alleles [33]. Parvez et al. applied NetMHCPan,
NetCTL and NetMHCII servers to predict T-cell epitopes while
BepiPred 2.0 and ABCPred were used for prediction of linear B-
cell epitopes in the SARS-CoV-2 genome [34]. The prediction of
class I MHC epitopes was made based on the binding score of
NETMHCPan4.0, followed by the affinity to be processed by the
cytosolic pathway provided by NetCTL 1.2. Epitopes having a
high binding affinity to MHC class I molecules and a high
ability to be transported by TAP will have a higher probability
to function as cytotoxic T-lymphocyte (CTL) epitopes. A total
of 54 MHC class I epitopes have been identified and four pro-
miscuous epitopes which can bind to different alleles were
found in the spike protein and they are WTAGAAAYY, CVA-
DYSVLY, VRFPNITNL and TRFQTLLAL. Twenty-one CD4þ T-
cell epitopes were identified based on the binding affinity toMHC class II by using NetMHCII 2.3. There were 24 out of 45 B-
cell epitopes found in the S protein of SARS-CoV-2, making it
the highest number of predicted B-cell epitopes across all the
SARS-CoV-2 proteins [34]. The immunoinformatics approach
has been used by Mishra et al. to identify potential T-cell
epitopes from structural and non-structural proteins for
immunotherapy against SARS-CoV-2. Two different predic-
tion algorithms, NetCTLpan and PickPocket, were used to
generate consensus epitopes against 12 HLA supertypes (HLA-
A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-
A*26:01, HLA-B*07:02, HLA-B*08:01, HLA-B*27:05, HLA-
B*39:01, HLA-B*40:01, HLA-B*58:01, HLA-B*15:01) and 57 epi-
topes have been identified in the key proteins of SARS-CoV-2.
Many of these epitopes formed a tight cluster around
consensus sequences MGYINVFAFPFTIYSLLLC and
KVSIWNLDYIINLI across the ORF6 and ORF8 proteins [35].
Grifoni et al. listed dominant SARS-CoV-1 T-cell epitopes
based on the response factor score and HLA restrictions.
Fourteen SARSCoV-2 T-cell epitopes with 100% identity to
SARS-CoV-1 were identified when SARS-CoV-2 T-cell epitopes
were mapped against SARS-CoV-1. Only one out of the ten
identified SARS-CoV-2 B-cell epitope sequences, FGA-
GAALQIPFAMQMAYRFNGI, shared a 100% identity with SARS-
CoV-1 after sequence alignmentwas performed [36]. Fast et al.
identified a list of high potential T-cell epitopes through an
analysis of human antigen presentations and ranked them
based on their likely coverage of presentations by MHC-I and
MHC-II alleles. Importantly, the epitope SYGFQPTNGVGYQPY
was highly ranked based on MHC presentations and contains
predicted promising B-cell epitopes. This epitope is localized
near the S protein receptor-binding domain (RBD), suggesting
its potential to trigger B-and T-cell responses [37]. In silico
analysis identified 17 peptides representing both B- and T-cell
epitopes and 13 peptides representing only T-cell epitopes
based on the highest HLA scores, as well as B-and T-cell
epitope counts. These findings provided us with valuable in-
formation to design highly conserved B- and T-cell epitope-
based peptide vaccines against SARS-CoV-2 [38]. However,
these epitopes have been generated using peptide prediction
algorithms and may not represent the natural peptides pre-
sented onHLA class I and class II molecules of the SARS-CoV-2
Table 5 Predicted SARS-CoV-2 T-cell epitopes in the S protein.
CD4þ T-cell CD8þ T-cell
Sequence No of studies References Sequence No of studies References
AAAYYVGYLQPRTFL 3 [34,37,38] YLQPRTFLL 7 [31,32,34,35,37,38,44]
APHGVVFLHVTYVPA 2 [37,38] KIADYNYKL 5 [33,34,38,44,45]
SYGFQPTNGVGYQPY 2 [37,38] RLFRKSNLK 5 [34,36,38,44,45]
HWFVTQRNFYEPQII 2 [36,38] NYNYLYRLF 5 [31,34,36,38,41]
YLYRLFRKSNLKPFERDI 2 [36,38] WTAGAAAYY 4 [32,34,37,38]
GVVFLHVTYVPAQEK 2 [34,38] GVYFASTEK 4 [32,34,38,44]
IIAYTMSLGAENSVA 2 [34,36] QIYKTPPIK 4 [34,36,38,45]
EFVFKNIDGYFKIYS 2 [38,44] VLNDILSRL 3 [34,36,38]
VYYHKNNKS 2 [38,45] GVYYHKNNK 3 [34,38,45]
VFNATRFAS 2 [34,45] FIAGLIAIV 3 [34,36,38]
YQTQTNSPR 2 [38,45] SIIAYTMSL 3 [36e38]

































b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 024infected cells. Additionally, prediction algorithms sort poten-
tial peptides based on the predictedMHC binding scores. Most
often, only the top scoring or dominant peptides are chosen
for follow up studies, but it is likely that some of the epitopes
that are naturally associated with class I molecules do not
follow such sorting criteria. Potent peptides could have been
missed with such stringent cut-offs, including those peptides
that have lower binding affinities. Therefore, the functional
activities of these predicted peptides representing CD4þ and
CD8þ T-cell epitopes should be further evaluated by experi-
mental validations such as the secretion of IFN-g and the
expression of a degranulation marker such as CD107a and
granzyme B by flow cytometry.
Studies on the SARS-CoV-1 epidemic in 2003 have shown
that adaptive immune responses towards the spike (S)glycoprotein were protective [39,40]. Hence, characterization
and detection of SARS-CoV-2 spike glycoprotein (S)-reactive
CD4þ T-cells in peripheral blood are likely to be critical in
inducing protective antibody responses. Braun et al. (2020)
demonstrated the presence of S-reactive CD4þ T-cells in 83%
of COVID-19 patients and 34% of SARS-CoV-2 seronegative
healthy donors (HD). Two overlapping peptide pools spanning
the entire S protein that comprised different counts of MHC II
epitopes were identified. The peptide pools comprised 21 and
13 predicted MHC II epitopes covering the N- and C-terminal
regions, respectively. S-reactive CD4þ T-cells were identified
by co-expression of 4-1BB and CD40L on the PBMCs isolated
from COVID-19 patients after peptide stimulations. The ma-
jority of S-reactive T-cells in COVID-19 patients co-expressed






































































































































































































































































































































































































































































































































































































































































b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 0 25during viral infections [17]. Nine MHC I epitopes clustering in
the receptor-binding domain and S2 domain were identified
by stimulating the splenocytes with pools of 15-mer over-
lapping peptides spanning the SARS-CoV-2, SARS-CoV-1, and
MERS-CoV S protein. T-cell responses were validated by using
IFN-Ɣ ELISPOT analysis [41]. Grifoni et al. reported the pres-
ence of SARS-CoV-2-specific CD8þ and CD4þ T-cells in ~70%
and 100% of convalescent samples, respectively, from pre-
dominantly mild COVID-19 patients. CD8þ T-cell responses
were detected against immunogenic peptides not only from
the S protein but also from M, N, nsp6 and ORF3a. CD4þ T cell
responses were also detected in 40e60% of unexposed in-
dividuals, suggesting pre-existing SARS-CoV-2-cross-reactive
T cell responses in certain healthy individuals [42]. For B-cell
epitopes, Poh et al. have identified two linear epitopes on the
SARS-CoV-2 S protein that elicited neutralizing antibodies in
COVID-19 patients. Potent B-cell epitopes in the sera of
COVID-19 and SARS patients were assessed by using pools of
overlapping linear B-cell peptides spanning the entire S pro-
tein of SARS-CoV-2 or SARS-CoV-1. Two distinct peptide pools
from the SARS-CoV-2 S peptide library, pools S14 and S21,
were strongly recognized by sera from COVID-19 patients [43].
In an effort to select promising T-cell epitopes that were
predicted by bioinformatics, CD4þ and CD8þ T-cell epitopes
that were predicted to be present in the spike (S) protein of
SARS-CoV-2 from a total of 11 different publications were
compared [Table 5]. Among the top seven highly potent CD8þ
T-cell epitopes (reported in at least four studies), both
YLQPRTFLL and WTAGAAAYY were present in a single pep-
tide (P6) “WTAGAAAYYVGYLQPRTFLLKYKKKKK” reported in
the study of Feng et al. Additionally, the top CD4þ T-cell
epitope “AAAYYVGYLQPRTFL” predicted from bioinformatics
analysis was also present in the P6 peptide sequence, sug-
gesting that this peptide might contain the potent epitopes
needed to trigger effective CD4þ and CD8þ T-cell responses.
Short peptides such as the P10 peptide “NYNY-
LYRLFRKSNLKPFERDISTEI” reported by Feng et al. contained 3
potent CD8þ T-cell epitopes which were reported in at least
three studies. Comparative analysis of prediction from
different servers will narrow down the number of epitopes
that have to be verified through experimental approaches for
the selection of immunodominant CD4þ and CD8þ T-cell
epitopes.
Some of the epitopes presented in [Table 5] can be observed
to overlap with epitopes from [Tables 2 and 3], further con-
firming that the predicted T-cell epitopes are promising epi-
topes that bind to MHC class I and II molecules. A few
potential epitopes that represent B- and T-cell epitopes from
the S protein were identified after amalgamating information
gathered from [Tables 2e5] and are presented in [Table 6].
Epitope sequences “WTAGAAAYYVGYLQPRTFLLKY”, “NYNY-
LYRLFRKSNLKPFERDISTEI”, “SYGFQPTNGVGYQPYRVVVLS-
FELLHAPAT”, “FPQSAPHGVVFLHVTYVPAQEK”, and
“CASYQTQTNSPRRARSVASQSIIAYTMSL” are the top candi-
dates as they not only exhibit positive IFN-g production, but
they also exhibit high global HLA population coverages.
Furthermore, these five epitopes are also capable of inducing
both CD4þ and C8þ T-cell responses, in contrast to the
epitope sequence “VPAQEKNFTTAPAICHDGKAHFPREGVFV”
which is implicated to only induce CD4þ T-cell responses.
b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 026Even though both epitope sequences “VPAQEKNFTTA-
PAICHDGKAHFPRE GVFV” and “GTKRFDNPVLPFNDGVYFAST”
show high immunogenicity and binding affinity scores, they
have relatively low global HLA population coverages. More-
over, epitope sequences “NYNYLYRLFRKSNLKPFERDISTEI”,
“SYGFQPTNGVGYQPYRVVVLSFELLHAPAT”, and
“CASYQTQTNSPRRARSVASQSIIAYTMSL” contain overlapping
B-cell epitope sequences presented in [Table 4]. All of the
epitopes listed in [Table 4] contain B-cell epitopes predicted by
the ABCPred server with threshold value of 0.51. However, our
stringent cut offs ensure that the B-cell epitopes are linear and
not conformational, highly antigenic, and are easily accessible
from the surface.
T-cell epitope prediction servers such as the IEDB T-cell
prediction server, NetMHC, NetMHCpan, NetMHCIIpan, and
NetCTL are commonly utilized. These servers leverage on
data-driven analysis over structure-basedmethods and utilize
machine learning to overcome problems with non-linearity of
peptide-MHC binding data. This allows researchers to
formulate predictions based on the binding affinity of peptides
to MHC molecules in addition to addressing the issue of the
discrimination of MHC binders to nonbinders. All the afore-
mentioned servers employ ANN algorithms while IEDB uses
QAM in addition to ANN which further enhances binding af-
finity predictions. Furthermore, pan-MHC methods such as
NetMHCpan and NetMHCIIpan were used to further improve
predictions of peptide binding affinities to uncharacterized
HLA alleles. On the other hand, common servers such as
BepiPred2.0 and ABCPred are used to predict linear B-cell
epitopes. Similar to the common T-cell epitope predicting
servers, BepiPred2.0 and ABCPred leverage on machine
learning algorithms as well. BepiPred uses a Random Forest
algorithm whereas ABCPred uses ANN. These methods have
been known to outperform B-cell epitope prediction servers
that are solely based on amino acid propensity scales.Design of multi-epitope peptide-based vaccines
In silico prediction revealed peptides presented by HLA class I
and class II molecules to CD4þ and CD8þ T-cells, respectively.
Predicted immunodominant T-cell epitopes can be used for
rational design of multi-epitope peptide-based vaccines but
effectiveness as immunogenic epitopes when presented as
short peptides need to be validated. Alternatively, synthetic
genes can be constructed to encode these immunogenic
peptideswhich can be cloned into vectors like pcDNA or pVAX
to generate DNA vaccines which can continuously express the
antigens [46,47]. A DNA-based vaccine, INO-4800, was
designed to encode the SARS-CoV-2 S protein. The immuno-
genicity of INO-4800 was demonstrated in multiple animal
models. The DNA vaccine was able to induce antibodies that
blocked S protein binding to host receptors and elicited good
INF-g levels on Day 10 post immunization. The use of adju-
vants has been reported to further enhance the immunoge-
nicity of vaccines [48,49]. For example, Montanide ISA 51 in
combination with a cocktail of HIV-derived peptide antigens
(containing a mixture of peptide specifying B- and T-cell epi-
topes) enhanced the immunogenicity of the antigenic peptide
[50]. The epitopes can also be fused with adjuvant proteins[e.g., toll-like receptor (TLR) ligands] which can be encapsu-
lated or displayed on the surface of nanoparticles [e.g., poly
lactic-co-glycolic acid (PLGA)] to elicit sustained T-cell re-
sponses and increase long term protection [8,51,52].
Several successful studies have led to the rational designs
of epitope-based peptide vaccines. For example, Flunisyn™,
Flu-V and Multimeric-001 (M-001) peptide-based influenza
vaccine candidates are currently in clinical Phase I, IIb and III
evaluations, respectively. FP-01.1 (Flunisyn™) is a novel syn-
thetic influenza A vaccine consisting of six fluorocarbon-
modified 35-mer conserved epitopes of influenza A NP, M,
PB1 and PB2 proteins. The peptide vaccine carried multiple
CD4þ and CD8þ T-cell epitopes and was shown to generate
robust CD4þ and CD8þ T-cell immunity in phase I clinical trial
[53]. Flu-V is a multi-epitope peptide vaccine comprising 4
peptides representing CD8þ T-cell epitopes originating from
conserved regions in internal proteins M1, NPA, NPB and M2
from influenza A and influenza B. A single dose of FLU-v with
adjuvant Montanide ISA 51 led to a significant reduction in the
number of influenza symptoms in 40% of participants when
compared to those receiving placebo (64.3%) [54]. M-001 is a
DNA vaccine carrying nine conserved genes encoding B- and
T-cell epitopes from the HA (four B and one CD4þ T-cell epi-
topes), NP (Two CD8þ and one CD4þ T-cell epitope), and M1
(one peptide that contains both B and CTL epitope) proteins of
both influenza type A and type B strains. The genes encoding
nine conserved linear epitopes (repetitions of three epitopes)
were cloned into a vector and a recombinant protein (M001)
was expressed in Escherichia coli. Administration of M001
vaccine with Montanide ISA 51VG adjuvant successfully
induced production of antibodies and IFN-g in humans [55].
Vacc-Flu is another peptide-based influenza vaccine candi-
date which contained one peptide to induce B-cell responses
and three peptides to induce T-cell responses to conserved
regions in the M2 and NP influenza A virus proteins. Peptide
selection was conducted using a proprietary peptide design
platform technology focusing on responses to human leuko-
cyte antigen (HLA)-restricted epitopes. Immunization of Vacc-
Flu into C57BL/6 and HLA-A2 transgenic mice resulted in the
induction of IFN-g-producing T-cells and influenza-specific
antibodieswhich protectedmice from influenza infection [56].
Peptides often lack immunogenicity and are susceptible to
enzymatic digestion. Therefore, effective vaccine delivery and
adjuvant systems which can enhance the immunogenicity
and protect the peptide vaccines will need to be incorporated
in the vaccine formulation [57]. PLGA is a non-toxic, FDA and
European Medicines Agency approved polymer and is widely
used as a vehicle for drug and vaccine delivery [58]. The size of
the nanoparticle can also affect the uptake efficiency and the
induction of immune response by APCs. Smaller PLGA NPs
(350 nm) enable better internalization by DCs and led to a
sustained cellular immune response in mice [59]. PLGA-NP
encapsulated peptide antigens are being protected from
enzymatic degradation in vivo until they are taken up by
antigen-presenting cells (APCs) and led to induction of robust
B- and T-cell responses [60,61]. Intranasal delivery of PLGANP-
entrapped inactivated porcine reproductive and respiratory
syndrome virus (PRRSV) vaccine adjuvanted with soluble
Mycobacterium tuberculosis whole cell lysate was observed to
enhance antigen-specific IFN-g secreting T-cell responses and
b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 0 27also led to enhanced production of high-affinity neutralizing
antibodies which induced a cross-protective immune
response in pigs [62]. A multi-peptide vaccine containing five
overlapping peptide sequences covering amino acids 693e777
(unit B/C) of the E2 protein of classical swine fever virus (CSFV)
was shown to completely protect pigs from lethal CSFV chal-
lenge [63]. Entrapment of H1N1 influenza virus-derived pep-
tides in PLGA nanoparticles was demonstrated to enhance T-
cell responses and vaccine efficacy in pigs [64].
Epitope-based peptide vaccine was also designed for the
Middle East Respiratory Syndrome Coronavirus (MERS-COV).
Several conserved B- and T-cell epitopes were identified in the
S protein of MERS-COV which might elicit protection against
MERS-COV infection. In particular, MHC class-I peptide
YKLQPLTFL and MHC class-II peptide YCILEPRSG were pre-
dicted as highly antigenic whilst QLQMGFGITVQYGT dis-
played the highest antigenicity-score among the B-cell
epitopes [65]. However, validation of these peptides as T-cell
epitopes is needed.
Two different adverse syndromesmight be associatedwith
vaccine-enhanced COVID-19 disease: antibody-dependent
enhancement (ADE) and vaccine-associated enhanced respi-
ratory disease (VAERD). ADE is a phenomenon in which
binding of a virus to non-neutralizing antibodies enhances its
entry into host cells through Fc receptors. VAERD occurs when
there is increased production of Th2 cytokines (IL-4, IL-5 and
IL-13) which can lead to airway hyper-responsiveness and
lung histopathology [66]. Most SARS-CoV-2 vaccines under
development are aiming to elicit an immune response against
the spike protein but previous studies showed that vaccine
platforms expressing the whole SARS-CoV-1 S glycoprotein or
using the whole inactivated virus was inducing enhanced
respiratory disease which resulted in adverse lung pathology
in animal models [67,68]. Inactivated MERS-CoV vaccine has
been shown to increase eosinophil infiltrations and Th2
cytokine productions, leading to lung immunopathology after
challenge in mice [69]. Thus, the usage of truncated proteins
such as the receptor-binding domain (RBD) or the S1 subunit
of the S protein could lead to the induction of neutralizing
antibodies and avoid ADE. Therefore, the precise selection of
CD4þ, CD8 T-and B-cell epitopes is important to develop a safe
and efficacious vaccine against SARS-CoV-2.Conclusions
DNA and RNA vaccines are new technologies which enable
rapid production of unconventional vaccines. These vaccine
platforms have never been applied to any previously licensed
human vaccines. The specific delivery method to attain high
immunogenicity is currently one of the frontier problems of
DNA vaccines while mRNA vaccines are poor in stability and
may lack immunogenicity due to low translational efficiency
[70]. Other platforms such as inactivated vaccines (IVs) and
live attenuated vaccines (LAVs) are established platforms
approved by the US FDA for many licensed human vaccines.
Most of the licensed vaccines approved by the US Food and
Drug Administration against viral infections to date are live-
attenuated or inactivated vaccines. Despite the ability of
LAVs to elicit lifelong immunity, it is associated with the riskof reversion to the wild type and requires extensive safety
monitoring. Moreover, the large-scale productions of LAVs
and IVs are laborious and require containment facilities for
growing the live SARS-CoV-2 and subsequent purification
processes. To meet the world's demand of millions of doses of
vaccine, there will be significant safety risks involved in the
growth of the pathogen and downstream processing.
China's leading vaccine manufacturers Sinovac and Sino-
pharm have provided reassuring information on their inacti-
vated vaccine candidates. The phase II clinical trial results of
Sinovac's vaccine candidate, CoronaVac, showed that it
induced neutralizing antibodies 14 days after vaccination. The
neutralizing seroconversion rate of CoronaVac was over 90%
in 600 healthy volunteers in phase II of their phase I/II study
conducted in Brazil. This infers that CoronaVacwas capable of
inducing a positive immune response. Moreover, Sinopharm
reported that their inactivated vaccine candidate triggered a
strong neutralizing antibody response in all 1120 participants
in the 28-day dosing schedule which only employed a middle-
strength dosage in their phase I/II study. Additionally, the
seroconversion rate for the 14-day and 21-day schedules of
the mid-dose was 97.6% and 100% at 28 days.
The selection of B-cell, CD4þ and CD8þ T-cell epitopes
based on bioinformatic predictions will require further
experimental validations such as ex-vivo stimulations by the
respective peptides to measure functional T-cell responses.
Immunogenicity study of peptides are required to confirm
their ability to elicit long term protection in animal models.
For B-cell epitopes, quantifications and comparisons of the B-
cell epitope-specific IgG titres against the RBD domain, or to
other conformational epitopes are required by isolating
monoclonal antibodies (mAB)s targeting the selected epitopes.
Furthermore, the persistence level of these antibodies against
linear and other conformational epitopes have to be thor-
oughly investigated. Phylogenetic analysis of the SARS-CoV-2
S protein should also be performed to determine the evolu-
tionary relationship of SARS-CoV-2 with other coronaviruses
such as SARS-CoV and MERS-CoV. This would help to locate
highly conserved epitopes that could be used for construction
of multi-epitope vaccine that can confer broad protection
against coronaviruses.
The success of both mRNA-1273 by Moderna and Ad5-
nCOV by CanSino in their phase I/II clinical trials have pro-
vided valuable information. mRNA-1273 evoked neutralizing
antibody titer levels generally observed in convalescent sera
within their initial 45 participants. It is also generally safe and
provided complete protection in a mouse challenge model.
Ad5-nCoVwas capable of significantly increasing neutralizing
antibodies after 28 days post-vaccination, in addition to spe-
cific T-cell responses. Furthermore, no serious adverse effects
were reported, and only mild to moderate adverse effects
were observed in 75%e83% of the participants [71,72].
Several multi-epitope vaccines against SARS-CoV-2 were
designed by connectingmultiple predicted B-, CD4þ and CD8þ
T-cell epitopes to an adjuvant using EAAAK linkers [44,73].
However, the ability ofmulti-epitope peptide-based vaccine in
eliciting immune responses and conferring protection against
SARS-CoV-2 requires a thorough investigation. In silico ap-
proaches of identifying specific immunogenic epitopes would
help to rationally design a multi-epitope peptide vaccine that
b i om e d i c a l j o u r n a l 4 4 ( 2 0 2 1 ) 1 8e3 028could serve the urgent need for an effective SARS-CoV-2
vaccine.
In conclusion, we have analysed the SARS-CoV-2 genome
for both B- and T-cell epitope candidates. We then further
reinforced our predictionswith pre-existing data from various
bioinformatics publications. Finally, we have indicated seven
multi-epitope sequences where five of the sequences we
believe could be integral in the development of an effective
peptide-based vaccine that is highly immunogenic and has a
wide global population coverage. However, in vitro evaluation
and in vivo trials are necessary to confirm the effectiveness of
these peptide-based vaccines. Such experimental validations
will be essential to help prioritize the selection of immuno-
genic epitopes and hasten vaccine designs during this un-
precedented crisis.Conflicts of interest
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